| | | | | | | | | | | | | | | | |
| |
![Collapse](/DXR.axd?r=1_87-p7f1t) | Issue Date FY: 2024 ( Subtotal = $117,821,689 ) (Continued on the next page) |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AI176298 | A Randomized Clinical Trial of Continuous vs. Intermittent Infusion Vancomycin: Effects on Measured GFR and Kidney Injury Biomarkers | 000 | 2 | NIH | 12/7/2023 | $177,113 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL168085 | Development of a Percutaneous Double Lumen Cannula-Based Cavopulmonary Assist System Toward Clinical Application | 000 | 1 | NIH | 1/31/2024 | $663,863 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01ES032396 | A university-community partnership to reduce exposure to disinfection byproducts in Appalachia | 000 | 4 | NIH | 11/3/2023 | $484,636 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL166225 | Targeting smooth muscle cell BMAL1 as a new therapeutic strategy against restenosis | 001 | 2 | NIH | 6/26/2024 | $53,197 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL166225 | Targeting smooth muscle cell BMAL1 as a new therapeutic strategy against restenosis | 000 | 2 | NIH | 12/14/2023 | $598,473 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21HL166178 | Precise in vivo gene editing of HSPC for the treatment of genetic hematologic diseases | 000 | 2 | NIH | 12/13/2023 | $191,250 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R35GM155281 | Cellular and Molecular Determinants of Post-Burn Myopathy | 000 | 1 | NIH | 7/18/2024 | $363,005 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31DA057812 | Role of Dynamic Signaling of NRG3-ErbB4 in the Prefrontal Cortex in Mediating Nicotine Withdrawal Phenotypes | 001 | 1 | NIH | 4/30/2024 | $1,280 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31DA057812 | Role of Dynamic Signaling of NRG3-ErbB4 in the Prefrontal Cortex in Mediating Nicotine Withdrawal Phenotypes | 000 | 1 | NIH | 12/27/2023 | $47,694 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | G08LM014412 | DASH-ing to Heart Health: Supporting Low-Income African American Women with an Interactive "Meals that Heal" Resource Book | 000 | 1 | NIH | 12/20/2023 | $118,770 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AI180274 | Molecular mechanisms of Helicobacter pylori trans-kingdom DNA conjugation | 000 | 1 | NIH | 11/22/2023 | $192,814 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00AR081367 | Contribution of ribosome specialization to the pathophysiology of muscular dystrophy | 001 | 3 | NIH | 7/12/2024 | $87,494 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00AR081367 | Contribution of ribosome specialization to the pathophysiology of muscular dystrophy | 000 | 3 | NIH | 1/11/2024 | $249,000 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K99AG084892 | Gabapentin prescription and health-related outcomes in older adults | 000 | 1 | NIH | 12/15/2023 | $89,895 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | NU58DP007724 | EMPOWER: Empowering and Mobilizing Intergenerational Community Partners to Reduce Menthol & Flavored Tobacco Use Among At-risk Communities in Kentucky | 00 | 2 | CDC | 7/2/2024 | $375,000 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01ES034786 | Mechanisms of Sex-specific Metabolic Disruption Caused by Organophosphate Flame Retardant Exposure | 000 | 1 | NIH | 7/1/2024 | $429,135 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R25ES027684 | Summer Research in Environmental Health Sciences | 000 | 7 | NIH | 10/23/2023 | $135,000 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21NS135089 | Cannabidiol (CBD) as a Potential Therapeutic for Experimental Subarachnoid Hemorrhage | 000 | 1 | NIH | 12/5/2023 | $229,500 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01HL149984 | Pharmacological Mechanistic Insights into Thoracic Aortic Aneurysm | 001 | 4 | NIH | 7/13/2024 | $75,600 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01HL149984 | Pharmacological Mechanistic Insights into Thoracic Aortic Aneurysm | 000 | 4 | NIH | 12/21/2023 | $162,000 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK124774 | Circadian Regulation of Metabolic Risk in Mice and Women: Role of Estrogen and Time-Restricted Feeding | 001 | 4 | NIH | 5/6/2024 | $33,963 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK124774 | Circadian Regulation of Metabolic Risk in Mice and Women: Role of Estrogen and Time-Restricted Feeding | 000 | 4 | NIH | 1/29/2024 | $509,460 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA053070 | Functional and Genomic Signatures of Escalated Fentanyl Use | 001 | 4 | NIH | 4/29/2024 | $64,145 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA053070 | Functional and Genomic Signatures of Escalated Fentanyl Use | 000 | 4 | NIH | 12/14/2023 | $577,309 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS116068 | Macrophage Depletion Therapy for Spinal Cord Injury | 001 | 4 | NIH | 4/17/2024 | $43,377 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS116068 | Macrophage Depletion Therapy for Spinal Cord Injury | 000 | 4 | NIH | 12/18/2023 | $557,698 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK124626 | Mechanisms for activation of beige adipose tissue in humans | 001 | 4 | NIH | 5/7/2024 | $36,546 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK124626 | Mechanisms for activation of beige adipose tissue in humans | 000 | 4 | NIH | 12/15/2023 | $548,202 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG066724 | Novel gastrocnemius muscle characteristics in peripheral artery disease patients associated with impaired functional performance | 001 | 4 | NIH | 5/13/2024 | $31,413 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG066724 | Novel gastrocnemius muscle characteristics in peripheral artery disease patients associated with impaired functional performance | 000 | 4 | NIH | 11/16/2023 | $282,711 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG070830 | Contributions of astrocyte RelA signaling in aging-related neurodegenerative sequelae following TBI | 001 | 4 | NIH | 5/23/2024 | $66,535 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG070830 | Contributions of astrocyte RelA signaling in aging-related neurodegenerative sequelae following TBI | 000 | 4 | NIH | 12/14/2023 | $598,802 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K23DK128562 | Classical and Alternative Renin-Angiotensin System Dysregulation in Sepsis-Associated AKI: A Reverse Translation Approach | 001 | 3 | NIH | 3/11/2024 | $0 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K23DK128562 | Classical and Alternative Renin-Angiotensin System Dysregulation in Sepsis-Associated AKI: A Reverse Translation Approach | 000 | 3 | NIH | 11/21/2023 | $157,563 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01ES033767 | Phthalate-Induced Dysregulation of Prostaglandin and Angiogenic Function During Ovulation in Women | 000 | 3 | NIH | 10/23/2023 | $439,396 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K08DK124566 | Muscle bone interaction and its role in diabetic bone disease of Type I diabetes | 000 | 4 | NIH | 12/19/2023 | $164,517 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK128033 | Mirabegron and tadalafil effectiveness for treatment of prediabetes | 001 | 3 | NIH | 5/7/2024 | $18,360 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK128033 | Mirabegron and tadalafil effectiveness for treatment of prediabetes | 000 | 3 | NIH | 12/15/2023 | $275,400 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG080589 | APOE Allele Switching as a Therapeutic Approach for Alzheimer's Disease | 001 | 2 | NIH | 4/30/2024 | $64,226 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG080589 | APOE Allele Switching as a Therapeutic Approach for Alzheimer's Disease | 000 | 2 | NIH | 11/29/2023 | $578,038 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F31MH132194 | The Experience and Regulation of Posttraumatic Shame among Women with Histories of Interpersonal Trauma | 000 | 2 | NIH | 11/15/2023 | $47,694 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AG077495 | Drug repurposing for Alzheimer’s disease-related inflammation caused by a TBI | 001 | 2 | NIH | 5/6/2024 | $19,125 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AG077495 | Drug repurposing for Alzheimer’s disease-related inflammation caused by a TBI | 000 | 2 | NIH | 11/29/2023 | $172,125 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AI177008 | Developing Statistical Methods on Event History Data Subject to Data Complexities for HIV Disease Progression and Policy Evaluation | 001 | 2 | NIH | 5/23/2024 | $20,029 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AI177008 | Developing Statistical Methods on Event History Data Subject to Data Complexities for HIV Disease Progression and Policy Evaluation | 000 | 2 | NIH | 1/29/2024 | $180,259 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01AG070279 | Cognitive Aging Trajectories in Survivors of Trauma | 000 | 2 | NIH | 1/17/2024 | $125,795 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AI184710 | Interactions between drug combinations and resistance acquisition risk for antimalarial ATP4 inhibitors | 000 | 1 | NIH | 6/7/2024 | $777,072 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG081356 | Phase I Cell Therapy for Maintaining Cholinergic Circuits in the Spectrum of Alzheimer’s Disease | 000 | 1 | NIH | 6/13/2024 | $659,568 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P40OD019794 | Ambystoma Genetic Stock Center | 001 | 10 | NIH | 5/3/2024 | $299,828 |
|